Truist analyst Richard Newitter lowered the firm’s price target on Lantheus to $100 from $110 and keeps a Buy rating on the shares as part of a broader research note on MedTech. The sector continues to trade down on fear of exposure to GLP-1s, and even good Q3 earnings may not matter amid a GLP-1 sector overhang, the analyst tells investors in a research note. While Truist continues to believe that the dramatic GLP1-driven sector pullback is likely overdone and that “narrative” is driving indiscriminate selling more so than a tangible fundamental impact, it’s hard to say when/if the GLP-1 overhang will subside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LNTH:
- William Blair biotech analyst to hold an analyst/industry conference call
- Lantheus program validated by Point Biopharma buyout, says Mizuho
- Eli Lilly deal for Point puts radiopharma names in spotlight
- JMP Securities remains bullish on Lantheus after Lilly’s acquisition of Point Biopharma
- Point Biopharma deal reads positively to radiopharma names, says B. Riley
